M42 has signed a Memorandum of Cooperation (MoC) with Yamagata University in Japan to accelerate research and innovation in heavy ion therapy, an advanced and highly precise form of radiation therapy for cancer treatment.
This partnership underscores M42’s commitment to pioneering patient-centric, world-class cancer care powered by cutting-edge technology and innovative medical solutions.
The agreement follows M42 and Cleveland Clinic Abu Dhabi’s recent partnership with Toshiba Energy Systems and Solutions Corporation (Toshiba ESS) to establish the region’s first heavy ion therapy facility in Abu Dhabi. This groundbreaking initiative will introduce one of the most advanced and effective cancer treatment technologies to the Middle East, positioning Abu Dhabi as a global hub for oncology innovation.
According to the statement, “With no heavy ion therapy center within a five-hour flight of the UAE, the upcoming facility, strategically located on the Cleveland Clinic Abu Dhabi campus, adjacent to Fatima bint Mubarak Center, the region’s first-of-its-kind comprehensive cancer center, will significantly enhance access to this life-saving treatment for patients across the Middle East.”
Hasan Jasem Al Nowais Group CEO & MD – M42 Chairman – Cleveland Clinic Abu Dhab
“We are delighted to partner with Yamagata University, the second-largest university in the Tohoku Region and home to Japan’s newest state-of-the-art heavy ion therapy facility. This partnership marks a critical step in our mission to advance oncology care and clinical research. By combining our expertise and fostering close collaboration, we are confident that this alliance will drive innovation in cancer care, expand the clinical applications of heavy ion therapy, and establish new benchmarks for the future of healthcare, both regionally and globally.”
Satoru Nagase, Dean of the Faculty of Medicine at Yamagata University said that, “Partnering with M42 allows us to expand the global reach of this groundbreaking therapy, helping to shape the future of oncology care. By sharing our knowledge and advancing research together, we are not only strengthening scientific collaboration but also improving access to highly effective cancer treatment options for patients in need.”
“This partnership represents a pivotal milestone in our ongoing mission to advance oncology care and clinical research. Through the combination of our collective expertise and a strong spirit of collaboration, we are poised to drive meaningful innovation in cancer treatment, broaden the clinical use of heavy ion therapy, and help shape the future of healthcare both regionally and on the global stage,” noted Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi.
Heavy ion therapy
Heavy ion therapy is an advanced form of radiation therapy used to treat cancer, especially tumors that are hard to treat with conventional methods. It offers precision in targeting and destroying cancerous tumors with minimal damage to surrounding healthy tissue, revolutionizing cancer care and addressing a critical gap in advanced treatment options in the UAE and beyond.
